Safety and value driving Phase IV growth at CROs; EVP

By Gareth Macdonald

- Last updated on GMT

Related tags: Vice president, Contract research organization

Increased focus on post-market safety and value has resulted in CROs handling more Phase IV work, according to a PharmaNet EVP, and this trend may continue as regulators seek real world evidence.

Jeff Trotter, executive vice president of Phase IV development at PharmaNet, told Outsourcing-Pharma that “the real world is real important​”. In recent years post-market safety has become increasingly important, boosting Phase IV business for contract research organisations (CRO).

This is now being accompanied by increased focus on value. Trotter said this spans other indications, cost-effectiveness and comparative effectives. More and more regulators will request post-approval data to prove a product has lived up to promise, said Trotter.

In April PharmaNet made three executive appointments to its Phase IV team.

Related news

Show more

Related products

show more

Next generation ePRO from SQN Health

Next generation ePRO from SQN Health

Syne Qua Non Clinical | 16-May-2018 | Business Advice

In an era of rapid technology growth, healthcare requires low cost solutions for real-time data collection. We have come a long way from paper to EDC and...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

Related suppliers

Follow us

Featured Events

View more


View more